These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 19083283)

  • 1. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.
    Hasnain M; Vieweg WV; Fredrickson SK; Beatty-Brooks M; Fernandez A; Pandurangi AK
    Prim Care Diabetes; 2009 Feb; 3(1):5-15. PubMed ID: 19083283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment settings and metabolic monitoring for people experiencing first-episode psychosis.
    Batscha C; Schneiderhan ME; Kataria Y; Rosen C; Marvin RW
    J Psychosoc Nurs Ment Health Serv; 2010 Sep; 48(9):44-9. PubMed ID: 20795590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes.
    Edward KL; Rasmussen B; Munro I
    Arch Psychiatr Nurs; 2010 Feb; 24(1):46-53. PubMed ID: 20117688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness.
    Vergara-Rodriguez P; Vibhakar S; Watts J
    Pharmacol Ther; 2009 Dec; 124(3):269-78. PubMed ID: 19647020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
    Schneiderhan ME; Batscha CL; Rosen C
    Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic syndrome and schizophrenia.
    Meyer JM; Stahl SM
    Acta Psychiatr Scand; 2009 Jan; 119(1):4-14. PubMed ID: 19133915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of metabolic syndrome in serious mental illness.
    Ganguli R; Strassnig M
    Psychiatr Clin North Am; 2011 Mar; 34(1):109-25. PubMed ID: 21333843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and mental illness.
    Newcomer JW
    Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.
    de Leon J
    J Clin Psychopharmacol; 2008 Apr; 28(2):125-31. PubMed ID: 18344721
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
    De Hert M; van Eyck D; De Nayer A
    Int Clin Psychopharmacol; 2006 Mar; 21 Suppl 2():S11-5. PubMed ID: 16601508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management.
    Cobaugh DJ; Erdman AR; Booze LL; Scharman EJ; Christianson G; Manoguerra AS; Caravati EM; Chyka PA; Woolf AD; Nelson LS; Troutman WG
    Clin Toxicol (Phila); 2007 Dec; 45(8):918-42. PubMed ID: 18163235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of bipolar disorders and metabolic syndrome: implications for primary care.
    Bell PF; McKenna JP; Roscoe BM
    Postgrad Med; 2009 Sep; 121(5):140-4. PubMed ID: 19820282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
    Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
    J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Swedish clinical guidelines--prevention and management of metabolic risk in patients with severe psychiatric disorders.
    Gothefors D; Adolfsson R; Attvall S; Erlinge D; Jarbin H; Lindström K; von Hausswolff-Juhlin YL; Morgell R; Toft E; Osby U;
    Nord J Psychiatry; 2010 Oct; 64(5):294-302. PubMed ID: 20662682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
    Stein K
    J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
    [No Abstract]   [Full Text] [Related]  

  • 18. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs.
    Laugharne J; Waterreus AJ; Castle DJ; Dragovic M
    Australas Psychiatry; 2016 Feb; 24(1):62-6. PubMed ID: 26635377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of care for cardiovascular disease and diabetes amongst individuals with serious mental illness and those using antipsychotic medications.
    Scott D; Platania-Phung C; Happell B
    J Healthc Qual; 2012; 34(5):15-21. PubMed ID: 22092725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.